Pulmonary sarcoidosis
diseaseOn this page
Also known as lung sarcoidosissarcoidosis of lung
Summary
Pulmonary sarcoidosis (MONDO:0001708) is a disease and 29 clinical trials. Top therapeutic interventions include canakinumab, corticotropin, and hydroxychloroquine. A subtype of interstitial lung disease specific to adulthood — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 29
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pulmonary sarcoidosis |
| Mondo ID | MONDO:0001708 |
| MeSH | D017565 |
| DOID | DOID:13406 |
| ICD-10-CM | D86.0 |
| NCIT | C34997 |
| SNOMED CT | 24369008 |
| UMLS | C0036205 |
| MedGen | 19873 |
| GARD | 0022993 |
| Anatomy (UBERON) | UBERON:0002048 |
| Is cancer (heuristic) | no |
Also known as: lung sarcoidosis · sarcoidosis of lung
Disease family
Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › interstitial lung disease specific to adulthood › pulmonary sarcoidosis
Related subtypes (1): Langerhans cell histiocytosis specific to adulthood
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Hydroxychloroquine | Phase 3 (in late-stage trials) |
| Mycophenolic Acid | Phase 3 (in late-stage trials) |
| Prednisone | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Canakinumab, Pentoxifylline.
Clinical trials & evidence
Clinical trials
Clinical trials: 29.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 12 |
| PHASE2 | 6 |
| PHASE3 | 4 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02188017 | PHASE4 | UNKNOWN | Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) |
| NCT05415137 | PHASE3 | ACTIVE_NOT_RECRUITING | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis |
| NCT00262132 | PHASE3 | TERMINATED | Mycophenolate for Pulmonary Sarcoidosis |
| NCT02200146 | PHASE3 | COMPLETED | Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). |
| NCT02824419 | PHASE2/PHASE3 | UNKNOWN | Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis |
| NCT05247554 | PHASE3 | UNKNOWN | Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis |
| NCT05890729 | PHASE1/PHASE2 | RECRUITING | A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis |
| NCT06169397 | PHASE2 | ENROLLING_BY_INVITATION | An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis |
| NCT06205121 | PHASE2 | RECRUITING | Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis |
| NCT00001877 | PHASE2 | COMPLETED | Treatment of Pulmonary Sarcoidosis With Pentoxifylline |
| NCT01732211 | PHASE2 | TERMINATED | A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis |
| NCT02888080 | PHASE2 | COMPLETED | Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis |
| NCT03824392 | PHASE1/PHASE2 | COMPLETED | Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis |
| NCT04064242 | PHASE2 | COMPLETED | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis |
| NCT01169038 | PHASE1 | COMPLETED | Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis |
| NCT01440192 | PHASE1 | TERMINATED | Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis |
| NCT00701207 | EARLY_PHASE1 | COMPLETED | Study of Nicotine Patches in Patients With Sarcoidosis |
| NCT00001532 | Not specified | RECRUITING | Role of Genetic Factors in the Development of Lung Disease |
| NCT03755245 | Not specified | ENROLLING_BY_INVITATION | Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis |
| NCT06853834 | Not specified | RECRUITING | Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis |
| NCT00828828 | Not specified | COMPLETED | Antibody Response to Influenza Vaccine in Patients With Sarcoidosis |
| NCT01384123 | Not specified | UNKNOWN | Rehabilitation in Pulmonary Sarcoidosis: a Prospective Study |
| NCT01587001 | Not specified | COMPLETED | The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis |
| NCT02044939 | Not specified | COMPLETED | Pulmonary Rehabilitation in Patients With Sarcoidosis |
| NCT03599414 | Not specified | COMPLETED | CASPA: CArdiac Sarcoidosis in PApworth |
| NCT04173689 | Not specified | COMPLETED | The Effect of Inspiratory Muscle Training and Breathing Exercises Combined With Upper Extremity and Trunk in Patients With Sarcoidosis |
| NCT04318392 | Not specified | COMPLETED | Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study |
| NCT05368883 | Not specified | COMPLETED | Comparison of Different Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis |
| NCT06113991 | Not specified | UNKNOWN | Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CANAKINUMAB | 4 | 1 |
| CORTICOTROPIN | 4 | 1 |
| HYDROXYCHLOROQUINE | 4 | 1 |
| MYCOPHENOLATE MOFETIL | 4 | 1 |
| MYCOPHENOLIC ACID | 4 | 1 |
| PENTOXIFYLLINE | 4 | 1 |
| METHIONINE | 3 | 1 |
| 5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINE | 2 | 1 |
| CENPLACEL-L | 2 | 1 |
| DOTA-NOC | 2 | 1 |
| CHEMBL1234268 | 0 | 1 |
| RACEMETHIONINE | -1 | 1 |